CN113874508A - 非病毒dna载体及其用于表达苯丙氨酸羟化酶(pah)治疗剂的用途 - Google Patents

非病毒dna载体及其用于表达苯丙氨酸羟化酶(pah)治疗剂的用途 Download PDF

Info

Publication number
CN113874508A
CN113874508A CN202080035845.8A CN202080035845A CN113874508A CN 113874508 A CN113874508 A CN 113874508A CN 202080035845 A CN202080035845 A CN 202080035845A CN 113874508 A CN113874508 A CN 113874508A
Authority
CN
China
Prior art keywords
cedna
itr
pah
itrs
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080035845.8A
Other languages
English (en)
Chinese (zh)
Inventor
D·A·科尔
P·萨马约亚
N·西尔弗
M·齐奥科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generational Biology Co
Original Assignee
Generational Biology Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generational Biology Co filed Critical Generational Biology Co
Publication of CN113874508A publication Critical patent/CN113874508A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16001—Phenylalanine 4-monooxygenase (1.14.16.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080035845.8A 2019-03-13 2020-03-13 非病毒dna载体及其用于表达苯丙氨酸羟化酶(pah)治疗剂的用途 Pending CN113874508A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962817771P 2019-03-13 2019-03-13
US62/817,771 2019-03-13
US201962857514P 2019-06-05 2019-06-05
US62/857,514 2019-06-05
PCT/US2020/022595 WO2020186150A2 (en) 2019-03-13 2020-03-13 Non-viral dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah) therapeutics

Publications (1)

Publication Number Publication Date
CN113874508A true CN113874508A (zh) 2021-12-31

Family

ID=72426457

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080035845.8A Pending CN113874508A (zh) 2019-03-13 2020-03-13 非病毒dna载体及其用于表达苯丙氨酸羟化酶(pah)治疗剂的用途

Country Status (12)

Country Link
US (1) US12415002B2 (cg-RX-API-DMAC7.html)
EP (1) EP3938515A4 (cg-RX-API-DMAC7.html)
JP (2) JP7583732B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210149702A (cg-RX-API-DMAC7.html)
CN (1) CN113874508A (cg-RX-API-DMAC7.html)
AU (1) AU2020235121A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021017852A2 (cg-RX-API-DMAC7.html)
CA (1) CA3133330A1 (cg-RX-API-DMAC7.html)
IL (1) IL286283A (cg-RX-API-DMAC7.html)
MX (1) MX2021011037A (cg-RX-API-DMAC7.html)
SG (1) SG11202109830TA (cg-RX-API-DMAC7.html)
WO (1) WO2020186150A2 (cg-RX-API-DMAC7.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115772503A (zh) * 2022-08-16 2023-03-10 广东省南山医药创新研究院 一种表达pah的基因修饰细胞药物及其制备方法与应用
CN116507730A (zh) * 2020-09-16 2023-07-28 世代生物公司 封闭端dna载体及其用于表达苯丙氨酸羟化酶(pah)的用途
CN116656740A (zh) * 2023-05-30 2023-08-29 浙江大学 一种腺相关病毒基因治疗载体及其在制备治疗苯丙酮尿症的药物中的应用
CN119876192A (zh) * 2024-07-02 2025-04-25 浙江大学滨江研究院 用于治疗苯丙酮尿症的多核苷酸

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021252952A1 (en) * 2020-06-11 2021-12-16 Sangamo Therapeutics, Inc. Methods and compositions for expressing phenylalanine hydroxylase
MX2023001109A (es) 2020-07-27 2023-04-24 Anjarium Biosciences Ag Composiciones de moleculas de adn, metodos para elaborar las mismas, y metodos de usos de las mismas.
GB202014751D0 (en) * 2020-09-18 2020-11-04 Lightbio Ltd Targeting vector
KR20230079172A (ko) 2020-10-01 2023-06-05 젠자임 코포레이션 간-유도 유전자 대체 요법에 의한 pku의 치료를 위한 인간 pah 발현 카세트
CN121532216A (zh) * 2023-04-18 2026-02-13 赛仁生物技术公司 腺相关病毒载体组合物和使用方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018126112A1 (en) * 2016-12-30 2018-07-05 The Trustees Of The University Of Pennsylvania Gene therapy for treating phenylketonuria
WO2018167621A1 (en) * 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
WO2018187231A2 (en) * 2017-04-03 2018-10-11 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
WO2018222925A1 (en) * 2017-05-31 2018-12-06 Ultragenyx Pharmaceutical Inc. Therapeutics for phenylketonuria
CN109195636A (zh) * 2016-03-03 2019-01-11 马萨诸塞大学 用于非病毒基因转移的末端封闭型线性双链体dna
WO2019032898A1 (en) * 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. NUCLEIC ACID MOLECULES AND USES THEREOF

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101511373B (zh) * 2006-06-19 2015-12-09 阿斯克肋匹奥生物制药公司 用于基因治疗的修饰的因子ⅷ和因子ⅸ基因和载体
EP2500434A1 (en) 2011-03-12 2012-09-19 Association Institut de Myologie Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109195636A (zh) * 2016-03-03 2019-01-11 马萨诸塞大学 用于非病毒基因转移的末端封闭型线性双链体dna
WO2018126112A1 (en) * 2016-12-30 2018-07-05 The Trustees Of The University Of Pennsylvania Gene therapy for treating phenylketonuria
WO2018167621A1 (en) * 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
WO2018187231A2 (en) * 2017-04-03 2018-10-11 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
WO2018222925A1 (en) * 2017-05-31 2018-12-06 Ultragenyx Pharmaceutical Inc. Therapeutics for phenylketonuria
WO2019032898A1 (en) * 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. NUCLEIC ACID MOLECULES AND USES THEREOF

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
无: "NG_008690.2", 《GENBANK》 *
无: "NM_000277.3", 《GENBANK》 *
无: "NM_008777.3", 《GENBANK》 *
无: "U49897.1", 《GENBANK》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116507730A (zh) * 2020-09-16 2023-07-28 世代生物公司 封闭端dna载体及其用于表达苯丙氨酸羟化酶(pah)的用途
CN115772503A (zh) * 2022-08-16 2023-03-10 广东省南山医药创新研究院 一种表达pah的基因修饰细胞药物及其制备方法与应用
CN115772503B (zh) * 2022-08-16 2023-10-17 广东省南山医药创新研究院 一种表达pah的基因修饰细胞药物及其制备方法与应用
CN116656740A (zh) * 2023-05-30 2023-08-29 浙江大学 一种腺相关病毒基因治疗载体及其在制备治疗苯丙酮尿症的药物中的应用
CN119876192A (zh) * 2024-07-02 2025-04-25 浙江大学滨江研究院 用于治疗苯丙酮尿症的多核苷酸

Also Published As

Publication number Publication date
US12415002B2 (en) 2025-09-16
MX2021011037A (es) 2021-12-15
IL286283A (en) 2021-10-31
WO2020186150A3 (en) 2020-10-29
US20230024354A1 (en) 2023-01-26
CA3133330A1 (en) 2020-09-17
JP2025016685A (ja) 2025-02-04
JP7583732B2 (ja) 2024-11-14
BR112021017852A2 (pt) 2021-11-30
EP3938515A4 (en) 2022-12-28
SG11202109830TA (en) 2021-10-28
JP2022525302A (ja) 2022-05-12
WO2020186150A2 (en) 2020-09-17
AU2020235121A1 (en) 2021-11-04
KR20210149702A (ko) 2021-12-09
EP3938515A2 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
US20250282848A1 (en) Non-viral dna vectors and uses thereof for expressing fviii therapeutics
JP2023126487A (ja) 無細胞合成から得ることができる閉端DNAベクターおよびceDNAベクターを得るためのプロセス
JP7583732B2 (ja) フェニルアラニンヒドロキシラーゼ(pah)治療薬を発現するための非ウイルス性dnaベクターおよびその使用
CN113316640A (zh) 包含对称的被修饰的反向末端重复序列的被修饰的封闭端dna(cedna)
CN113454232A (zh) 封闭端dna(cedna)产生中对rep蛋白活性的调节
US20240181085A1 (en) Non-viral dna vectors and uses thereof for expressing pfic therapeutics
US20230138409A1 (en) Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
US20230134550A1 (en) Non-viral dna vectors and uses thereof for expressing gaucher therapeutics
US20240026374A1 (en) Closed-ended dna vectors and uses thereof for expressing phenylalanine hydroxylase (pah)
JP2023542132A (ja) Fviii治療薬を発現させるための非ウイルス性dnaベクター及びその使用
CN116529369A (zh) 非病毒dna载体及其用于表达fviii治疗剂的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination